Page last updated: 2024-11-04

ropinirole and Bradykinesia

ropinirole has been researched along with Bradykinesia in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Ropinirole was weakly neuroprotective in this model."1.32S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. ( Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Millan, MJ1
Di Cara, B1
Hill, M1
Jackson, M1
Joyce, JN1
Brotchie, J1
McGuire, S1
Crossman, A1
Smith, L1
Jenner, P1
Gobert, A1
Peglion, JL1
Brocco, M1

Other Studies

1 other study available for ropinirole and Bradykinesia

ArticleYear
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 309, Issue:3

    Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopa

2004